Toxicogenomics enjoyed considerable attention as a ground-breaking addition to conventional toxicology assays at its inception. However, the pace at which toxicogenomics was expected to perform has been tempered in recent years. Next to cost, the lack of advanced knowledge discovery and data mining tools significantly hampered progress in this new field of toxicological sciences. Recently, two of the largest toxicogenomics databases were made freely available to the public. These comprehensive studies are expected to stimulate knowledge discovery and development of novel data mining tools, which are essential to advance this field. In this review, we provide a concise summary of each of these two databases with a brief discussion on the commonalities and differences between them. We place our emphasis on some key questions in toxicogenomics and how these questions can be appropriately addressed with the two databases. Finally, we provide a perspective on the future direction of toxicogenomics and how new technologies such as RNA-Seq may impact this field.
Toxicology has traditionally relied on animal testing to determine the risk of a chemical compound to humans based on well-established cytological, physiologic, metabolic, and morphologic endpoints (Suter et al., 2004) . The rodent model is commonly used to identify toxic substances such as carcinogens and reproductive toxins. Toxicological studies require a large number of animals to allow statistically significant conclusions to be drawn, and the 2-year carcinogenicity bioassays are routinely conducted to assess the potential of tumorigenicity in animals and relevant risk in humans. Consequently, the current toxicological testing is of high cost in terms of time, labor, compound Disclaimer: The views presented in this article do not necessarily reflect those of the U.S. Food and Drug Administration. synthesis, and animals used. It becomes a substantial investment in drug development and environmental health evaluation (Ulrich and Friend, 2002; Waters and Fostel, 2004) . Furthermore, animal testing is not a fail-safe paradigm (Olson et al., 2000) . There is a need to constantly improve safety testing strategies.
The value of microarray technology was quickly realized in the toxicology community soon after its introduction in the mid-1990s (DeRisi et al., 1996; Schena et al., 1995; Wodicka et al., 1997) , which has led to a new scientific subdiscipline termed toxicogenomics . Through integrating genomic technology with bioinformatics, toxicogenomics has enjoyed widespread attention as an alternative means to study the underlying molecular mechanisms of toxicity and address challenges that are difficult to overcome by conventional toxicology methods . The broader concept of toxicogenomics encompasses transcriptomics, proteomics, and metabolomics (Afshari et al., 2011; Cui and Paules, 2010) . In practice, microarray-based toxicogenomics is still the main application. With microarrays, expression levels of tens of thousands of genes can be simultaneously monitored, permitting the assessment of alterations in gene expression profiles induced by different compounds or associated with different physiological conditions. Importantly, the large number of genes tested together provides opportunities to identify gene patterns and signatures that provide unique insight into a drug's toxicity that are difficult to recognize by conventional technologies. Therefore, toxicogenomics was highly expected to revolutionize the traditional approaches for assessing toxicity (Boverhof and Zacharewski, 2006) and has been considered as a paradigm shift in toxicology.
Many studies have demonstrated the value of toxicogenomics (Ellinger-Ziegelbauer et al., 2008; Fielden et al., 2007; Gerecke et al., 2009; Huang et al., 2010; Low et al., 2011; Suter et al., 2003; Yang et al., 2006; Zidek et al., 2007) . For example, it has been suggested that toxicogenomics biomarkers can discriminate drug candidates that have a greater potential to cause toxicity in susceptible patient populations despite no conventional indicators of toxicity being observed in preclinical studies (McBurney et al., 2009 (McBurney et al., , 2012 . Equally, more sensitive biomarkers for early toxicity detection can be derived from a "subtoxic dose" in which the injury occurs at the molecular but not at the phenotypic level or in clinical chemistry measures (Lühe et al., 2005) . Ellinger-Ziegelbauer et al. (2008) applied a 14-day toxicogenomics design to develop a gene signature to distinguish genotoxic carcinogens from non-genotoxic carcinogens, an endeavor that usually requires the 2-year bioassay.
In this review, the publication trend in PubMed for toxicogenomics was analyzed, which exhibited the plateauing of the field. It is likely that the recent release of two large toxicogenomics databases in the public domain will stimulate knowledge discovery and data mining tool development. Subsequently, a concise summary of these databases is provided with a brief discussion on the commonality and differences among them. The focus is then shifted to key questions in toxicogenomics and how to appropriately address these questions with these databases. Finally, a perspective on the future direction of toxicogenomics is provided with a discussion on how RNA-Seq will impact this field.
ANALYSIS OF THE LITERATURE TREND OF TOXICOGENOMICS RESEARCH
The early success of toxicogenomics stimulated its widespread application. By surveying the publications indexed by PubMed using the "toxicogenomics" query (bar chart in Fig. 1A ), a rapid growth of publications was found during the period from 2000 to 2006. However, the growth has flatted since then. A decreased trend was observed in the Voluntary eXploratory Data Submission (VXDS) program of the US Food and Drug Administration (FDA) in Supplementary figure 1 (Goodsaid et al., 2010) , although the specific reasons are unknown. Some factors have been speculated to be responsible for the fading optimism, including the lack of uniform designs, multiplicity of normalization and analysis strategies, questionable reproducibility of microarray data across platforms, absence of data quality control measures and standards, and lack of effective data sharing and reporting (Boverhof and Zacharewski, 2006) . However, most of these issues are not toxicogenomics specific and thus are unlikely to be the key contributors to the slowing progress in toxicogenomics. For example, the use of microarrays in the genomics area as a whole has continually flourished (bar chart in Fig. 1B) . Moreover, some factors such as data sharing (Brazma et al., 2001 ), data quality control (Shi et al., 2006) , genomic biomarker development (Shi et al., 2010a) , and the need for careful phenotypic anchoring of genomics data in toxicology (Bammler et al., 2005; Beyer et al., 2007) have been adequately addressed in community-wide efforts. Thus, the factors contributing to the decline should be beyond the technology itself.
In the period of 2000-2010, by reading abstracts and associated Medical Subject Heading terms of the published papers containing the keyword "toxicogenomics," four categories can be defined: (1) "Review," (2) "Mechanism," (3) "Biomarker," and (4) "Others." As shown in Figure 2 , "Biomarker" and "Review" notably decreased since 2006, whereas both "Mechanism" and "Others" continued to increase. The analysis implies that although toxicogenomics remains a valuable tool for mechanistic study, its application for biomarker discovery and development has diminished.
Developing reliable and robust toxicogenomics biomarkers requires a large number of tested compounds (Ulrich and Friend, 2002) , and thus requires significant funding sources to conduct such studies. The FDA-led community wide MicroArray Quality Control Phase-II project selected three toxicogenomics datasets and three cancer microarray datasets (Shi et al., 2010b) . The sample size of the cancer datasets on average was significantly larger than those of the toxicogenomics datasets. More samples often mean better chances at finding more robust and better biomarkers, but also indicate a higher cost particularly for animal studies. By comparing the percentage of the projects funded by the National Institute of Health (NIH) using the query of "toxicogenomics" against "genomics," the percentage of NIH-funded projects was found to correlate with the percentage of publications in both fields during the period of 2000-2010 (solid line in Fig. 1) . Obviously, the proportion of NIH-funded projects for toxicogenomics slightly decreased after 2007 compared with still increased but with a smaller slop for genomics. The trend difference in NIH-funded projects between toxicogenomics and genomics is consistent with that in publications in PubMed, suggesting the lack of funding plays some role in the fading optimum on toxicogenomics.
TWO LARGE TOXICOGENOMIC DATASETS ARE NOW IN THE PUBLIC DOMAIN
Considering the significant cost involved in a large-scale toxicogenomics experiment, most reported studies (particularly those from the academic institutes) are small in terms of the number of compounds tested. This has limited the application of extensive and comprehensive bioinformatics approaches and thus reduced the essential knowledge discovery opportunity to enable interrogation of data beyond ontology and other "guilt-by-association" considerations in biomarker discovery.
In 2011, two large toxicogenomics databases were made freely available to the public: the Japanese Toxicogenomics Project (TGP or TG-GATEs) open-tggates/search.html; Uehara et al., 2010) . DrugMatrix was generated by Iconix Pharmaceuticals (Ganter et al., 2005) and was purchased and publicly released by the U.S. National Institute of Environmental Health Sciences recently (https://ntp. niehs.nih.gov/drugmatrix/index.html). Both databases place an emphasis on marketed drugs and liver gene expression data. Some drugs were tested equally by the TGP and DrugMatrix effort in multiple doses and treatment durations as well as in vitro and in vivo study designs. The biggest advantages of these two databases over the existing publicly available databases such as GEO (Barrett et al., 2005) , ArrayExpress (Brazma et al., 2003) , ArrayTrack (Tong et al., 2003) , CEBS (Waters et al., 2003) , and others (Burgoon et al., 2006; Hayes et al., 2005) are: (1) the uniform experimental design makes the comparative study between chemical treatments more straightforward and relevant; (2) the large number of marketed drugs profiled provides an unprecedented opportunity to comprehensively assess the utility of the microarray-based preclinical models for predicting human specific toxicity; and (3) both in vitro and in vivo studies for the same set of chemicals allow determination of the similarity and difference between two systems in predictive toxicology.
The TGP (Uehara et al., 2010) tested 170 compounds, mainly medicinal drugs. Supplemented with some kidney studies, their main target organ is the liver. Data from some 20,000 arrays were generated in both in vitro and in vivo experiments. As summarized in Table 1 , the in vivo experiments used male Sprague Dawley rats with two different experimental designs, single-and repeated-dose study. For both designs, a 1-week dose range finding study was performed first to determine the FIG. 1. The yearly publications and NIH-funded projects related to toxicogenomics (A) or genomics (B) compared with all publications/projects in a specific year. Publications and projects were queried from PubMed and Research Portfolio Online Reporting Tools (RePORT) of NIH (http://projectreporter.nih.gov/ reporter.cfm), respectively. The "genomics" query used keywords of (microarray OR "gene expression profiling" OR genomics). The "toxicogenomics" query used keywords of (toxicogenomics OR ((microarray OR "gene expression profiling" OR genomics) AND (toxicology OR carcinogenicity OR carcinogenesis OR tumorigenicity OR genotoxicity OR non-genotoxicity OR hepatotoxicity OR "liver toxicity" OR nephrotoxicity OR "kidney toxicity" OR "cardiovascular toxicity" OR cardiotoxicity OR immunotoxicity OR "reproductive toxicity" OR "skin sensitization" OR "cutaneous toxicity" OR "endocrine disruption" OR neurotoxicity OR "hematologic toxicity" OR "pulmonary toxicity" OR "gastrointestinal toxicity" OR "musculoskeletal toxicity" OR "urinary toxicity")).
NEW OPPORTUNITIES IN TOXICOGENOMIC RESEARCH maximum tolerated dose (MTD) of each compound. Based on these data (e.g., body weight and food changes, organ weight, and gross pathology), the MTD was set as the highest dose in the repeated-dose study. In the single-dose study, almost all compounds were treated at the same dose as their repeateddose study to facilitate comparison of gene expression between single-and repeated-dose studies. Specifically, in the singledose study, rats were treated in one of the three dose levels (low, medium, and high at a 1:3:10 ratio) with concurrent controls and sacrificed at 3, 6, 9, or 24 h after a single administration. In the repeated-dose study, rats were also treated at the three dose levels (low, medium, and high at a 1:3:10 ratio) with concurrent controls, but sacrificed at 24 h after the last dose of repeated administration for 3, 7, 14, and 28 days. For each dose/time group, the gene expression data were analyzed with three animals per group. Other data obtained include histological examination, blood chemistry, hematology, body weight, organ weight, and general symptoms. In addition, two types of in vitro studies, primary hepatocytes from Sprague Dawley male rats and human donors, were used. They were treated with three dose levels (low, medium, and high at ratio 1:5:25) with concurrent controls and harvested for gene expression analysis at 2, 8, and 24 h after treatment.
In the case of DrugMatrix (Ganter et al., 2005) , over 600 drugs were tested in vivo and in vitro using male Sprague Dawley rats. Two dose levels were applied in the in vivo experiments; the fully effective dose, defined as the dose used for treating disease (converted from human), and the MTD defined as 50% reduction in weight gain over control after 5 days of daily dosing. A maximum of 13 tissues including liver, kidney, heart, and bone marrow were harvested for gene expression analysis. Microarray studies were done after 0.25, 1, 3, and 5 (some were replaced with 7/14/30/90) days of first administration with 3 biological replicates in each group. The GE CodeLink RU1 10,000 rat array was applied to all the samples, whereas Affymetrix RG230-2.0 arrays were only used for ~5000 samples (about half are liver samples). Overall data from about 10,000 arrays are available from liver tissues. Histopathology analysis, serum chemistry test, hematology, organ weight, and gross observation were also performed. The in vitro experiments were done using primary hepatocytes harvested from male Sprague Dawley rats. Microarray analysis was performed at 16 and 24 h after the treatment. Table 1 summarizes key information about the two datasets. They both (1) are drug-centric; (2) primarily focus on the rat liver; (3) include substantial data for the kidney; (4) use the same Affymetrix array chip (Rat RG230-2.0) for gene expression profiling (the majority of samples in DrugMatrix were profiled with the CodeLink chip); and importantly, (5) include conventional toxicological data for predictive modeling and phenotypic anchoring. The high degree of commonality between two databases provides an opportunity for the cross-lab comparison and meta-analysis, including assessment of technical performance, transferability of genomic markers, statistically validating each others findings, and more.
The highest commonalities between TGP and DrugMatrix databases are that (1) both assayed a large number of marketed drugs, of which 73 drugs are in common; (2) both used the same male Sprague Dawley strain; and (3) similar in vitro and in vivo experimental designs were implemented in both studies. The high commonality between two databases provides a unique opportunity for cross-database comparison and meta-analysis. However, there are two key differences between two databases that need to be taken into account in the comparative analysis and meta-analysis. These are: (1) TGP used Affymetrix, whereas DrugMatrix predominately applied CodeLink, although some 5,000 arrays were also performed on the Affymetrix platform and (2) the determination of MTD is different.
It is worthwhile to mention another toxicogenomics dataset that was also released recently from a European effort. The InnoMed PredTox project (http://www.ebi.ac.uk/bioinvindex/ browse_studies.seam) was carried out among 14 pharmaceutical companies, 2 small-to-mid-sized enterprises, and 3 universities with a goal of discovering molecular mechanisms of liver and kidney toxicity . Drug candidates from the participating companies that were discontinued at the preclinical phase due to toxicological findings in the liver and/ or kidney were selected as test compounds, including 14 proprietary drug candidates and 2 reference toxic compounds (i.e., gentamicin and troglitazone). The male Wistar rat was the test species. The animals were divided into three groups (five rats per group and per time point), treated at two dose levels (low and high) with a concurrent vehicle controls. Dosages were selected based on pre-existing information with the aim of achieving target organ toxicity after 2 weeks of exposure with the high dose. The rats were sacrificed after 1, 3, or 14 days of repeated dosing following an overnight fasting period. Serum, plasma, blood, as well as liver and kidney tissues were collected at necropsy for further investigations. Conventional toxicological endpoints were collected alongside transcriptomics, proteomics, and metabolomics profiles for all animals. Thus, this is an interesting dataset for systems biology. However, we decide for not including it in this review due to the fact that it involves only 16 compounds, and their chemical identity is not disclosed. In addition, it uses a different rat strain (i.e., Wistar), which will complicate the cross-database analysis with TGP and DrugMatrix.
THE RISE OF NEW OPPORTUNITIES IN TOXICOGENOMICS
The two publically available databases together provide an unprecedented opportunity to revisit some of the important promises in toxicogenomics, paving the way to further advance toxicogenomics and its role in risk assessment and regulatory decision-making. Table 2 addressed by both databases. Some of these questions are discussed in more depth in the following subsections. This review is not meant to exhaustively discuss all the applications ever proposed in toxicogenomics. We do realize that some of these toxicogenomics applications are extremely important, such as toxicogenomics for the mechanistic study. The toxicogenomics-based mechanistic research has become a commonly accepted approach to study the molecular mechanisms underlying toxicity (Cui and Paules, 2010) , as illustrated in Figure 2 . Many reviews have summarized the mechanistic studies using toxicogenomics data (Blomme et al., 2009; Foster et al., 2007; Ulrich and Friend, 2002) . Nonetheless, the two databases provide a repository of ~30,000 liver gene expression profiles associated with ~500 drugs from a wide range of pharmaceutical indications, thus offering a significant advantage over any other datasets in the literature to study mechanisms of toxicity. We are also not going to discuss the concept and utility of the "reference" toxicogenomics database, an active field in the earliest days of toxicogenomics, because both TGP and DrugMatrix were developed at very beginning to serve that purpose by interrogating the potential toxicity liability of a compound based on its gene signature against these precalculated signatures using the entire set of compounds in the reference databases. Another important application in toxicogenomics which will not be discussed here is to develop microarray-based predictive models using the short-term toxicogenomics design for supplementing the 2-year carcinogenicity bioassay for such as non-genotoxic carcinogenicity, which were also investigated using both DrugMatrix (Fielden et al., 2007) and TGP .
Replacing Animal Models With In Vitro Assays Coupled With Toxicogenomics
In addition to ethical considerations, animal studies are resource-intensive regarding time and cost. Even short-term in vivo experiments still need a large quantity of compounds (g), and compound availability is frequently a limiting factor at the early stage of drug discovery. Meanwhile, animal welfare presents a strong incentive to reduce testing in animals. Efforts have been made to explore in vitro systems to supplement or even replace animal models for safety assessment of food additives, cosmetic chemicals, etc. A notable effort in Europe is to develop alternatives to animal testing by encouraging methods to "reduce, refine and replace" (3Rs) animal uses under the REACH (Registration, Evaluation and Authorization of Chemicals) initiative (Abbott, 2005) . In the United States, the FDA in its new initiatives in advancing regulatory science has promoted the effort of animal-free approaches with emphasis on testing methods based on in silico and in vitro approaches (Hamburg, 2011) .
Traditional in vitro cytotoxicity assays can reduce the compound requirement to the necessary level, but at that measure, endpoints such as cell lysis are of limited predictive value. Studies have demonstrated the potential of toxicogenomics-based in vitro systems for toxicity assessment. The early endeavor by Waring et al. (2001) was encouraging, followed by further demonstration using primary cultured rat hepatocytes to identify two
FIG. 2.
The trend of yearly publications related to (1) "Review," (2) "Biomarker," (3) "Mechanism," and (4) "Others" among those queried with the single keyword of "toxicogenomics." The publications were annotated based on Medical Subject Heading (MeSH) terms or reading abstracts. (1) "Review"-these publications are classified by MeSH as "review"; (2) "Biomarker"-it relates to development of classifiers or signature genes that separate different modes of action, chemical toxicity, or toxicity types; (3) "Mechanism"-it mainly involves identification of differentially expressed genes between two or more conditions (e.g., treated vs. control) that are subsequently used to identify altered pathways, gene/protein functions, and/or regulatory networks to understand the underlying mechanisms of toxicity; and (4) "Others"-the publications do not fall into any of the three aforementioned categories (most are commentary, database related, or development of novel algorithms).
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CHEN ET AL. toxicological classes (Yang et al., 2006) . However, it is not an unknown fact that in vitro systems are different from in vivo systems, particularly in metabolic functions that are specifically important for drug toxicity. By comparing various animal-free liver models against liver tissue in terms of their gene expression profiles, Boess et al. (2003) demonstrated that the gene expression of cultured primary hepatocytes has moderate similarity to the liver, whereas two selected cell lines are quite different from whole liver. The authors suggested that although in vitro experiments are an indispensable research tool, the limitations of the experimental design of cell culture studies should be kept in mind (Jaeschke, 2003) .
One aspect of toxicogenomics-based safety assessment is to determine the "guilt-by-association" between compounds and then relate such association to toxicity endpoints. Consequently, whether an in vitro system holds a potential to replace an in vivo system can be viewed as whether these two systems have the same "association" patterns. A reliable conclusion of such analysis is more pronounced if it is performed on a large number of compounds, for which the current literature evidence is limited. Fortunately, such an opportunity resides in both TGP and DrugMatrix where both in vitro and in vivo toxicogenomics studies were carried out for the same sets of compounds. Specifically, the TGP dataset provided 145 compounds tested in rat primary hepatocytes and 158 compounds tested in human primary hepatocytes, and the rat in vivo liver toxicity data for most of these compounds are available. DrugMatrix also provided gene expression data on rat primary hepatocytes for about 120 compounds, and about 60 of them also have the rat in vivo liver gene expression data.
TABLE 2 Key Issues/Questions in Toxicogenomics That Could Be Potentially Addressed by TGP and/or DrugMatrix Databases
Predictive toxicology
Replacing animal models with in vitro assays coupled with toxicogenomics
This is one of the major efforts, mainly under the REACH initiative in Europe, to develop alternative testing systems with the aim to improve the screening throughput and to reduce animal use and compounds tested.
Predicting toxicity prior to conventional endpoints
A short-term toxicogenomics study based on exposure time within a few days could provide the similar accuracy in toxicity assessment as this is commonly conducted in, e.g., the 28-day conventional animal study. This application allows integration of toxicity evaluation into an early stage of drug discovery, which could result in savings in both time and resources required for the conventional way of toxicity assessment.
Supplementing the 2-year bioassay with toxicogenomics
The 2-year bioassay is a norm to assess, e.g., non-genotoxic carcinogenicity. The successful application of toxicogenomics in this field will tremendously reduce cost, animal use, and time required for this type of safety assessment. Biomarkers
Reliable biomarker
It has been hypothesized and demonstrated in some cases that toxicogenomics improves specificity and/or sensitivity of the current toxicity biomarkers. For example, liver function tests such as elevated serum transaminases (e.g., AST, ALT) lack sensitivity for drug-induced liver injury. Toxicogenomics could generate more reliable biomarkers for liver injury.
"Subtox" biomarker
The "subtox" biomarker announces the existence of gene expression signals at a dose level where the conventional indicators of toxicity (e.g., clinical chemistry or histopathology) are not observed but occurs in a higher dose level. This has an important clinical implication in early diagnosis for, e.g., acetaminophen-induced liver injury.
Translational biomarker
It is hypothesized but with limited demonstration that toxicogenomics biomarkers can discriminate drug candidates that have the potential to cause toxicity in susceptible patients from drugs that do not have this potential despite no conventional indicators being observed in preclinical studies. Mechanism and mode of action
Reference database for categorizing chemicals
Given that a large number compounds has been profiled with microarray, different gene signatures corresponding specific mechanisms can be predetermined based on the group of compounds sharing the same mechanisms. Subsequently, the gene expression profile of an unknown agent (e.g., a single compound or a mixture) can be compared against these signatures, and putative mechanisms or mode of actions could be postulated for the unknown agent.
Drug-pair approach to study toxicity mechanisms
It is hypothesized that if two compounds are pharmacologically closely related with similar chemical structure but one is toxic whereas the other is not, the difference between two should be related to off-target events. With toxicogenomics, the off-target-related pathways can be examined via the side-by-side comparison of the pair to study underlying mechanisms of toxicity.
Phenotypic anchoring
This relates specific alterations in gene expression profiles to specific adverse effects defined by conventional parameters of toxicity. Consequently, the underlying mechanisms eliciting the toxicity can be understood to assist drug candidate selection and drug development decision making and can also be used to guide the design of follow-up experiments.
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Predict Toxicity Prior to Conventional Endpoints
The concept of molecular events preceding pathological endpoints in time has driven the development of short-term toxicogenomics assays for toxicity that are commonly assayed in a long-term animal study. For pharmaceutical companies, this means better prioritization of compounds in drug development and earlier identification of potential "show-stopping" toxicities . In other words, toxicogenomics can remove candidates with unacceptable safety margins in the early drug discovery process, which would result in tremendous savings in both time and resources (Yang et al., 2004) .
Since Afshari et al. (1999) proposed that gene expression changes could occur prior to the onset of pathological symptoms, many supportive findings have been published. Ruepp et al. (2005) claimed to find several examples in their study indicating an earlier detection of toxicological events by transcript profiling, which precedes pathology. For example, in the study of tacrine hepatotoxicity, the 6h transcript profiles flagged 4 out of 5 animals to have liver damage (cholestasis), but histological analysis did not find changes until 24 h. Roth et al. (2011) reported gene expressions changes in rat liver treated with a histamine-3 receptor agonist after a single acute administration. Their analysis of gene expression changes strongly suggested the development of toxicity while histopathology did not identify a clear liver toxicity; the toxicogenomics findings were confirmed in a 2-week repeated-dose rat study where prominent liver pathology occurred. However, the findings from other studies indicated otherwise. Foster et al. (2007) argued that in their 3-year research with an analysis of 33 compounds, they found toxicogenomics is no more or even less sensitive than the traditional endpoints of histopathology in some cases, particularly when histopathological changes are focal and multifocal in nature.
The controversial findings in the literature could stem from the small number of tested compounds studied, which limits the ability to draw conclusive results. The two large datasets contain detailed histological and clinical chemistry data, offering several ways to verify whether toxicogenomics is a more sensitive tool to detect toxicity compared with the conventional approach. For example, the TGP repeated-dose study was carried out at 3, 7, 14, and 28 days. Thus, the expression patterns and gene signatures from the shorter treatment duration (i.e., 3, 7, or 14 days) can be used against to the histopathological findings in the 28-day treatment to assess whether the molecular events in the early time points correlate with the pathological endpoints.
Translational Biomarkers
The safety assessment in humans relies heavily on animal studies, which requires a reliable translational biomarker from the tested animals that predict toxicity in humans. Of the compounds that cleared preclinical testing, a study showed that only 71% of all human toxicities can be reasonably predicted with animal models, and that the accuracy varied among different organs (Olson et al., 2000) . Toxicological changes occurring in preclinical species are not necessarily relevant to humans partly because of species differences in cell biology, physiology, or responses to changes induced by compounds. Moreover, despite the vigorous safety testing during the drug development process, rare adverse drug reactions (ADRs) of new medicinal products cannot be predicted at the time of market introduction. Thus, rare ADRs are a leading cause for the withdrawal of drugs from the market. There are two basic scenarios in which cross-species comparisons may be a challenge: (1) false positive, in which toxicities observed in animal models are not relevant to humans and (2) false negative, in which toxicities observed in human cannot be detected by animal models. An understanding of the molecular mechanisms of toxicological changes can help establish the relevance to humans (Yang et al., 2004) and thus develop better translational biomarkers to minimize false positives and false negatives.
The majority of toxicogenomics-based studies, particularly in the study of drug-induced liver injury (DILI), have focused on finding signals in animals for drugs that are missed with the conventional approach (scenario 2: false negative). Drugs (e.g., troglitazone) did not cause obvious liver toxicity in preclinical studies or during human clinical trials, but were found to cause severe liver injury in humans, albeit at a relatively low incidence, once the drug reached the market and was exposed to a large number of patients (Kaplowitz, 2005) . Whether toxicogenomics could help in identifying the liability of these compounds in animal models is still not clear, but some promising cases were reported. Lühe et al. (2005) reported a short-term rat study investigating three different antidiabetic compounds, in which histopathology findings indicated that two compounds caused steatosis, but the third one did not cause any visible signs of hepatotoxicity. However, rat gene expression profiling classified all three compounds as causing steatosis, and follow-up studies truly identified the third compound as causing steatosis in dogs with histopathology showing liver necrosis and microsteatosis. We also examined a toxicogenomics design using rats to predict human specific DILI but the results were disappointing (Zhang et al., 2012) .
Although the mechanistic investigation could lead to relevant translational biomarkers, profiling a large number of drugs for a comparative analysis is another way forward for translational biomarker discovery. This approach requires a large number of profiled drugs, some with human specific toxicity and others with no such potential. This requirement can be realized in both TGP and DrugMatrix but with a significant challenge. Both TGP and DrugMatrix contain gene expression data primarily for marketed drugs. Classifying a marketed drug as a toxic agent such as DILI is a challenge. For example, the distinction between DILI drugs and non-DILI ones could be a false dichotomy because the causality of some drugs and liver injury is difficult to establish. Thus, the utility of both TGP and DrugMatrix for translational biomarkers largely lies in how the marketed drugs are accurately annotated for certain toxicity such as DILI. Some of this information is available from the FDA drug labeling system. For example, we annotated the DILI potential in humans for 289 drugs of 389 tested compounds in the DrugMatrix dataset and for 128 drugs of 170 tested compounds in the TGP dataset (Chen et al., 2011) . The human toxicity data coupled with in vivo/in vitro toxicogenomics data in the TGP and DrugMatrix databases will benefit translational biomarker development for predicting human adverse events and mechanism studies for cross-species extrapolation.
Drug-Pair Approach to Study Toxicity Mechanisms
Some drugs are more prone to elicit toxicity than others despite sharing a similar chemical structure or being in the same therapeutic category with the same mode of action. Drug pair represents a pair of drugs that possess similar chemical structure and act on the same therapeutic target but display discordant toxic risk in humans (McBurney et al., 2009 (McBurney et al., , 2012 . One of the most striking examples is ibuprofen versus ibufenac. Both are non-steroidal anti-inflammatory drugs with only one methyl group setting them apart. Ibuprofen is an over-the-counter drug and it has been on the market more than 30 years with limited case reports for DILI. In contrast, ibufenac was marketed in 1966 and quickly withdrawn in February, 1968 due to severe hepatotoxicity. Late clinical studies demonstrated that ibufenac caused elevated alanine aminotransferase (ALT) in 12/36 patients and jaundice in 5/400 cases. The small difference in chemical structure but huge difference in human toxicity between a pair of drugs such as ibuprofen/ ibufenac makes the drug-pair approach specifically attractive to identify the mechanisms associating with one but not with the other in the pair. It has been suspected that if two compounds are pharmacologically closely related with similar chemical structures but one is toxic whereas the other is not, the difference between the two could be related to off-target events. With toxicogenomics, the off-target-related pathways can be exploited via a side-by-side comparison of a drug pair to delineate underlying mechanisms differentiating the pair.
We conducted a systematic analysis for both databases to determine the potential drug pairs for the DILI research. We define that two drugs are considered as a pair if they share the similar chemical structure with structure similarity > 0.5, and they share the same therapeutic effect that is defined in the fourth level of the Anatomical Therapeutic Chemical (ATC) system of the World Health Organization Collaborating Centre (http://www.whocc.no/), and they have a distinct DILI annotation based on the FDA-approved drug label. First, we assessed the chemical structure similarity between any pair of the compounds using the Tanimoto metric based on the extended connectivity fingerprints (ECFP-4) descriptors calculated using Pipeline Pilot (version 8.0, Accelrys Inc., San Diego, CA). As a result, 284 pairs with their Tanimoto similarity scores of ≥ 0.5 were identified. Secondly, therapeutic categories of each pair were compared based on the ATC system where drugs were classified in groups at five different levels according to the organ or system on which they act and their therapeutic, pharmacological, and chemical properties. Two drugs were considered as a potential pair if they belong to the same classification in the fourth level of ATC system (i.e., chemical subgroup). Finally, the difference in DILI risk between two drugs in a pair was assessed with their DILI classification based on the DILI scoring system using the FDA-approved drug labels (Chen et al., 2011) . Two scenarios were considered for a pair with different DILI risk: (1) one was most-DILI-concern, whereas the other is either less-DILI-concern or no-DILI-concern; and (2) both drugs are most-DILI-concern but one is a withdrawn drug and the other is still on the market. The analysis yielded 16 drug pairs as summarized in Table 3 , and their chemical structures were provided in Supplementary figure 2. Most identified drug pairs were from DrugMatrix, which might relate to the fact that the development of drug classes in DrugMatrix is based on structure-activity relationship. The availability of gene expression data for these 16 pairs in TGP and DrugMatrix offers a distinct opportunity to study DILI-specific mechanisms.
FUTURE PERSPECTIVE
Toxicogenomics enjoyed its widespread attention as a revolutionary alternative to conventional toxicology studies from its inception. However, the pace at which toxicogenomics was expected to have significant impact has flatted in recent years. Several areas of focus related to these two databases can be foreseen to advance toxicogenomics. First, the current toxicogenomics studies are still liver-dominant followed by kidney as evident in both discussed datasets. The organ complexity at the cellular level is a challenge. DrugMatrix contains minimum datasets for multi-organ gene expression profiles, whereas TGP only contains data for liver and kidney. Thus, toxicogenomics should progress into integration between organs and into other organs beyond the liver and kidney. Secondly, turning data into knowledge remains the challenge but with the development of advanced knowledge discovery and data mining tools using large datasets such as the opportunities offered by these two large databases, the next innovation cycle in toxicogenomics can be foreseen with bioinformatics.
Besides the need in developing effective knowledge discovery tools and entering inter-organ investigation, technology innovations will also impact the science of toxicogenomics. Notably, whole-transcriptome sequencing using next-generation sequencing technologies, i.e., RNA-Seq, is a newly emerging technology for both mapping and quantifying transcriptomes. Compared with DNA microarrays, RNA-Seq provides a more sensitive and precise measurement of transcript levels. RNA-Seq has a very low background signal and does not have an upper limit for quantification. Consequently, it has a large dynamic range of expression levels over which transcripts can be detected, estimated to be greater than 9000-fold (Nagalakshmi et al., 2008) . By contrast, DNA microarrays lack sensitivity for genes expressed either at low or very high levels and therefore have a NEW OPPORTUNITIES IN TOXICOGENOMIC RESEARCH much smaller dynamic range (hundreds fold level). Additionally, RNA-Seq has also been shown to be highly accurate for quantifying expression levels and has high levels of reproducibility for both technical and biological replicates (Marioni et al., 2008) . These improvements over DNA microarrays could provide new opportunities for toxicogenomics to identify more sensitive biomarkers, the biggest promise toxicogenomics offered. The most significant advantage associated with RNA-Seq is its ability to identify new types of biomarkers (alternative splicing, mutation, isoform-specific expression, non-coding RNA, etc.) which is difficult to realize with microarrays. The cost of RNA-Seq currently is comparable to microarrays and thus may eventually replaced microarrays and move toxicogenomics forwards toward fulfilling its old promises. However, critical assessment of RNA-Seq to toxicogenomics needs to be carefully conducted to understand whether the technology really adds the value to enhance our understanding of the underlying mechanism of toxicity, whether the technology delivers a better prediction system and whether the biomarkers from the large microarray databases such as these discussed in this review can be directly applied to RNA-Seq data. Currently, the FDA-led community-wide MAQC consortium is entering the third phase to address these issues. The results and conclusions from this SEquencing Quality Control (SEQC) project will shed the light on perspective use of RNA-Seq in toxicogenomics.
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